Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suvecaltamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I known ✓ | Q9P0X4 | 6/20 | 1.00 |
| ▸ | CACNA1H known ✓ | O95180 | 6/20 | 1.00 |
| ▸ | CACNA1G known ✓ | O43497 | 4/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suvecaltamide SCHEMBL21828396 | 1.00 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| Suvecaltamide SCHEMBL1065999 | 1.00 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1064366 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL8231799 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1058794 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL8231358 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1060457 | 0.90 | CACNA1I (0.82) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1060490 | 0.89 | CACNA1I (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1062188 | 0.89 | CACNA1I (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1062749 | 0.89 | CNR2 (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346817-A1 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022251812-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022216386-A9 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-4041225-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | Cavion, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |